高级检索
当前位置: 首页 > 详情页

A functional variant in CHK1 contributes to increased risk of nasopharyngeal carcinoma in a Han Chinese population.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China [2]Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China [3]Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China [4]National Clinical Research Center for Geriatric Disorders, Changsha, China [5]Key Laboratory of Translational Radiation Oncology, Hunan Province, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China [6]Department of Laboratory Medicine, National Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
出处:
ISSN:

关键词: biomarker checkpoint kinase 1 nasopharyngeal carcinoma single nucleotide polymorphisms susceptibility

摘要:
DNA damage checkpoints act as a supervisor by preventing the course of cell cycle upon DNA damage and keeping the steadiness of genome. Checkpoint kinase 1 (CHK1) cannot be ignore in the etiology of numerous human cancers including nasopharyngeal cancer (NPC). To discuss genetic polymorphisms of CHK1 rs492510 in the occurrence of NPC was our objective. Rs492510 polymorphism of CHK1 was genotyped in 684 patients with NPC and 823 cancer-free controls. We utilize logistic regression models to appraise the correlation of rs492510 and susceptibility of NPC. Comparative expression level about CHK1 in nasopharyngeal carcinoma tissues were determined by real-time polymerase chain reaction. And we made use of Dual-Luciferase Reporter Assay to assess the transcriptional ability of CHK1 with different rs492510 allele. Adjusting multivariate logistic regression based on age, sex, body mass index, smoking, and drinking status showed that CHK1 rs492510 GA + GG genotype carriers presented prominent higher risk in NPC (odds ratio = 1.376, 95% confidence interval: 1.087-1.742; P = .008). As a consequence, we revealed that CHK1 relative expression levels in NPC tissues was higher than rhinitis tissues. Besides, the expressions of CHK1 in rs492510 GA genotype carriers were higher compared with people in AA genotype. The G allele of rs492510 generated remarkable higher transcription activity of CHK1 vs A allele by luciferase reporter assay. Our study considered that single nucleotide polymorphism rs492510 could increase transcription activity of CHK1 with the functionality, contributing to the susceptibility of NPC. © 2020 Wiley Periodicals, Inc.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 生物学
小类 | 3 区 生化与分子生物学 3 区 细胞生物学
最新[2023]版:
大类 | 3 区 生物学
小类 | 3 区 生化与分子生物学 4 区 细胞生物学
第一作者:
第一作者机构: [1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China [2]Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China [3]Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China [4]National Clinical Research Center for Geriatric Disorders, Changsha, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China [2]Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China [3]Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China [4]National Clinical Research Center for Geriatric Disorders, Changsha, China [5]Key Laboratory of Translational Radiation Oncology, Hunan Province, Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China [*1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, 410008 Hunan, China. [*2]Key Laboratory of Translational Radiation Oncology, Hunan Province,Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013 Hunan, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号